Ezolid 400 - Tablet Linezolid - 400mg 10 Tablet(s) / Box ACI Limited Introduction: Ezolid 400 is an antibiotic medicine used in the treatment of severe bacterial infections. It is used to treat infections of lungs (Pneumonia), skin and soft tissues. Ezolid 400 may be taken with or without food, preferably at a fixed time. You should take it regularly as per the schedule prescribed by your doctor. Taking it at the same time every day will help you to remember to take it. Do not stop taking it until you have finished the complete course, even when you feel better. If you stop taking this medicine too early then infection may return or... Uses of Ezolid 400: Severe bacterial infections Side effects of Ezolid 400: VomitingHeadacheNauseaDecreased blood cells (red cells, white cells, and platelets)Diarrhea How to use Ezolid 400: Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Ezolid 400 may be taken with or without food, but it is better to take it at a fixed time. Avoid Ezolid 400 with tyramine-rich food such as cheese, smoked fish, meats and some types of beer. How Ezolid 400 works: Ezolid 400 is an antibiotic. It stops bacterial growth by preventing synthesis of essential proteins required by bacteria to carry out vital functions. Indication: Community-acquired pneumonia, Skin and skin structure infections, Nosocomial pneumonia Administration: May be taken with or without food. Adult Dose: Oral Uncomplicated skin and skin structure infections Adult: 400 mg 12 hrly for 10-14 days. Vancomycin-resistant Enterococcus faecium Adult: 600 mg 12 hrly for 14-28 days. Methicillin-resistant Staphylococcus aureus infections Adult: 600 mg bid for 7-21 days. Community-acquired pneumonia; Nosocomial pneumonia; Complicated skin and skin structure infections Adult: 600 mg 12 hrly for 10-14 days. Elderly: No dosage adjustment needed. Hepatic impairment: Mild to moderate: No dosage adjustment needed. Child Dose: Oral For Pediatric Patients Pneumonia, complicated skin infections, vancomycin resistant enterococci: Birth–11 y: 30 mg/kg/day q8h >11 y: 1,200 mg/day q12h Uncomplicated skin infections: Birth–5 y: 30 mg/kg/day q8h 5–11 y: 20 mg/kg/day q12h >11–18 y: 1,200 mg/day q12h Renal Dose: Renal impairment: No dosage adjustment needed. Contraindication: Linzolid formulations are contraindicated for use in patients who have known hypersensitivity to Linzolid or any of the other product components. Linzolid should not be used in patients taking any medicinal product which inhibits monoamine oxidases A or B (e.g. phenelzine, isocarboxazid) or within two weeks of taking any such medicinal product. Linzolid should not be administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis, carcinoid syndrome and/or patients taking directly and indirectly acting sympathomimetic agents (e.g. pseudoephedrine), vasopressive agents (e.g. epinephrine, norepinephrine), dopaminergic agents (e.g. dopamine, dobutamine), serotonin re-uptake inhibitors, tricyclic antidepressants, serotonin 5-HT1 receptor agonists (triptans), meperidine or buspirone. Mode of Action: Linezolid is a bacteriostatic oxazolidinone which acts by inhibiting ribosomal protein synthesis. It is active against gm+ve bacteria including vancomycin-resistant enterococci and MRSA. It has limited in vitro activity against gm-ve bacteria. Precaution: Preexisting myelosuppression, renal impairment (CrCl < 30ml/min), uncontrolled hypertension, phaeochromocytoma, carcinoid syndrome, untreated hyperthyroidism, chronic infection, history of seizures, bipolar depression, schizophrenia or acute confusional states. Pregnancy and lactation. Monitor complete blood counts weekly. Give after haemodialysis. Not known if linezolid or metabolites removed during peritoneal dialysis. Lactation: Unknown; use caution Side Effect: >10% Pediatrics Diarrhea (7.8-10.8%) 1-10% Headache (5.7-8.8%).Diarrhea (8.2-8.3%),Nausea (5.1-6.6%),Vomiting (2-4.3%),Dizziness (1.8-2.6%),Rash (1.1-2.3%),Vaginal moniliasis (1.1-1.8%),Taste alteration (1-1.8%),Oral moniliasis (0.5-1.7%),Abnormal LFTs (0.4-1.6%),Fungal infection (0.3-1.5%),Localized abdominal pain (1.2-1.3%),Tongue discoloration (0.3-1.3%),Generalized abdominal pain (0.9-1.2%) Pediatrics Vomiting (2.9-9.4%),Headache (0.9-6.5%),Anemia (5.6%),Thrombocytopenia (4.7%),Nausea (1.9-3.7%),Generalized abdominal pain (0.9-2.4%),Localized abdominal pain (0.5-2.4%),Loose stools (1.6-2.3%),Eosinophilia (0.4-1.9%),Pruritus, other than application site (0.8-1.4%),Vertigo (1.2%) 10-14 days), transient ischaemic attacks, renal failure, Stevens-Johnson syndrome. Interaction: May reduce serum levels w/ rifampicin and phenytoin. May cause hypoglycaemia w/ insulin or oral antidiabetics. May increase risk of seizures w/ tramadol. Potentially Fatal: Increased risk of serotonin syndrome w/ MAOIs, TCAs, SNRIs, or other serotonergic drugs (e.g. bupropion, vilazodone, mirtazapine, amoxapine, buspirone, maprotiline, meperidine, trazodone, nefazodone). Significant increase in BP w/ vasopressive agents (e.g. epinephrine, norepinephrine), sympathomimetic agents (e.g. pseudoephedrine) and dopaminergic agents (e.g. dopamine, dobutamine).